The combination of a $45.2M insider purchase cluster and a $25M PIPE at the IPO price is a strong bullish signal. Monitor the IPO pricing and any lock-up expiration dates. The cross-filing context (material agreement + insider cluster) amplifies the signal — insiders are putting significant capital at risk alongside the IPO. Expect positive price action at IPO and near-term support from insider alignment.
Price Chart
Executive Summary
Odyssey Therapeutics insiders and a major investor (TPG GP A, LLC) have made significant open-market purchases totaling ~$45.2M in the past week, concurrent with a $25M PIPE investment tied to the company's IPO. The cluster includes $25M from TPG, $20M from Director Li Nan, and $200K from Director Chu Shelley, alongside routine non-cash derivative conversions and a small tax withholding. The purchases coincide with a material share purchase agreement (filed 2 days ago) for a $25M PIPE at the IPO price, indicating insiders and cornerstone investors are signaling confidence in the IPO valuation.
Key Financial Metrics
Key Facts
- TPG GP A, LLC purchased 1,388,889 shares for $25,000,002 in open-market on 2026-05-11
- Director Li Nan purchased 1,111,111 shares for $19,999,998 in open-market on 2026-05-11
- Director Chu Shelley purchased 11,111 shares for $199,998 in open-market on 2026-05-11
- A $25M PIPE investment (Share Purchase Agreement) was signed on 2026-05-07, tied to the IPO price
- Total open-market purchase value is ~$45.2M, representing ~5.6% of the $805M market cap
- Non-cash transactions (derivative conversions, tax withholding) total $0 economic value
- The cluster includes 6 insiders, with 3 making open-market purchases and others executing non-cash transactions
Financial Impact
Open-market insider purchases total ~$45.2M, or ~5.6% of market cap, a highly material signal. The PIPE adds $25M in new equity capital at the IPO price.
Risk Factors
- IPO pricing below expectations could reduce the PIPE's signaling value
- Post-IPO lock-up expirations may lead to selling pressure from pre-IPO holders
- The company's pre-revenue status (biotech) carries fundamental execution risk
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ODTX-1778706680432 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $18.99 $19.00 | ▲ +0.05% | ▼ −0.47% | $19.30 (+1.63%) |
Aug 4, 2026 11w ago | 8-K | $19.96 $20.89 | ▲ +4.66% | ▲ +4.86% | $19.30 (−3.31%) |
Jun 17, 2026 18w ago | 8-K | $19.07 $18.72 | ▼ −1.84% | ▼ −1.52% | $19.30 (+1.21%) |
May 11, 2026 24w ago | Insider Cluster | $17.45 $17.90 | ▲ +2.58% | ▲ +2.72% | $19.30 (+10.60%) |
May 8, 2026 24w ago | 424B4 | $17.45 $17.90 | ▲ +2.58% | ▲ +2.72% | $19.30 (+10.60%) |
May 8, 2026 24w ago | EFFECT | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers